Recently, the 2024 Changchun International Medical and Health Industry Expo was held in Changchun, Jilin Province. This expo attracted 648 companies to participate, with a total investment of 18.604 billion yuan in signed projects, indicating that Changchun's pharmaceutical and health industry is gathering strong momentum. Statistics show that in the first 10 months of this year, the scale of the biopharmaceutical and life health industries in Changchun reached 92.5 billion yuan, a year-on-year increase of 10.2%.

Jilin Province has abundant medicinal resources, and Changchun is located in the central part of the province, with the advantage of deep processing and utilization of high-quality authentic medicinal materials within the province. At the same time, Changchun is one of the first three biomedicine industry bases recognized by the state, gathering many scientific research institutions such as Chunguang Machinery Institute, President of Chinese Science, Changchun Yinghua Institute, 49 colleges and universities such as Jilin University, Changchun University of Traditional Chinese Medicine, and has an innovation team led by a number of medical and health related professionals. Relying on solid scientific research advantages and industrial foundation, Changchun's pharmaceutical and health industry has made significant progress in recent years, with a number of leading enterprises emerging.

Jiefang Pharmaceutical Group is a large enterprise headquartered in Changchun that integrates scientific research, production, and marketing. At this expo, the company showcased multiple products and showcased the latest research and development achievements in the fields of traditional Chinese medicine and big health, attracting a large number of merchants to stop and consult and negotiate. The chairman of the company, Xiu Laigui, said that it is important for pharmaceutical companies to enhance their influence, but more importantly, to help people achieve "precise nutrition, precise prevention, precise medical treatment, precise rehabilitation, and precise health". This is an important focus for the next development of the traditional Chinese medicine health industry.

Shuangyang District, Changchun City has a long history of raising deer and is known as the "hometown of Chinese spotted deer". Jilin Dong'ao Deer Industry Group Co., Ltd., located in Shuangyang District, is a deep processing enterprise of the entire industry chain of sika deer, integrating "learning, research, production", "breeding, processing, and sales". The general manager of the company, Xu Hui, introduced that in addition to participating in this expo, the company has also participated in large-scale product exhibitions and sales at home and abroad multiple times, opening up the domestic market and helping Shuangyanglu products to go international.

It is reported that in recent years, Shuangyang District has formulated and introduced a series of policy measures in the breeding of high-quality Sika deer, standardized scale breeding, and deep processing, aiming to achieve a total output value of 20 billion yuan for the entire Sika deer industry chain by the end of 2025.

In April of this year, Changchun held a conference on high-quality development of the biopharmaceutical and life health industries, proposing that by 2025, the scale of the biopharmaceutical and life health industries in the city should exceed 100 billion yuan, and the number of enterprises should exceed 1000; Strive to double the industry scale to 200 billion yuan within another 5 years and enter the first tier of the national biopharmaceutical industry. Aiming at this goal, Changchun City is focusing on integrating high-quality resources and cluster development, and is planning to build Yongchun Biomedical City with high standards.

Wang Zilian, Mayor of Changchun, said, "We will further improve the policy of supporting the development of Yongchun and spare no effort to create a new highland of high-quality development in Changchun." Changchun plans to strive to complete more than 15 billion yuan of fixed assets investment in the core area of Yongchun Biomedical City by 2025, introduce more than 10 "chain owners" enterprises, enter the first echelon of the country in terms of new drug innovation ability, and strive to achieve 50 billion yuan of output value in the core area of biomedicine and life health industries by 2030.

It is reported that the "Several Measures to Support the Three Year Rapid Breakthrough Action Plan for Biopharmaceuticals and Life Health Industry in Changchun City (Trial)" issued in August 2023 has formulated relevant financial support policies in seven aspects: supporting the introduction of major projects, supporting fund investment, supporting new drug research and development, supporting high-end medical device research and development, supporting drug market authorization owners to entrust production, supporting platform construction, and supporting the gathering of high-end talents. Five special funds with a total scale of 2.3 billion yuan have been established, and three alliances have been formed for scientific and technological innovation, investment and financing, and medical industry collaboration, providing a high-quality environment for basic research and industrial development in the field of medicine and health, accelerating the creation of a domestic first-class, internationally renowned, and distinctive strategic emerging industry cluster worth billions of yuan.

Huang Xianyu, member of the Standing Committee of the CPC Changchun Municipal Committee and vice mayor of Changchun, introduced that in terms of supporting the introduction of major projects, Changchun will give subsidies of 10% to 30% of its total fixed assets investment to projects with a large amount of fixed assets investment in the fields of biomedicine and life health (not less than 200 million yuan in principle); For particularly significant projects, support can be provided through a "case by case" and "enterprise by policy" approach. At the same time, corresponding entrepreneurial funding support will be provided to academicians and their teams who start businesses in Changchun, and academicians will be supported in leading the establishment of innovation platforms to support the transformation of scientific and technological achievements and project construction.